Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease

Overview of attention for article published in BMC Nephrology, April 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (77th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

patent: 2 patents

Citations

dimensions_citation: 14 Dimensions

Readers on

mendeley: 39 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 2 patents that reference this research output.

Biomarker of polycystic kidney disease and uses thereof

Grant US-11116755-B2

United States of America

BIOMARKER OF POLYCYSTIC KIDNEY DISEASE AND USES THEREOF

Application WO-2017087409-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.